A study of the effect of conversion to enteric-coated mycophenolate sodium on quality of life in patients with gastrointestinal symptoms related to mycophenolate mofetil therapy after kidney transplantation (MYQOL).

Trial Profile

A study of the effect of conversion to enteric-coated mycophenolate sodium on quality of life in patients with gastrointestinal symptoms related to mycophenolate mofetil therapy after kidney transplantation (MYQOL).

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Mycophenolate sodium (Primary) ; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms MYQOL
  • Sponsors Novartis
  • Most Recent Events

    • 26 Feb 2009 Actual initiation date changed from May 2006 to Sep 2005 as reported by ClinicalTrials.gov.
    • 26 Feb 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov, last updated 26 Feb 2009.
    • 26 Feb 2009 Additional location identified as reported by ClinicalTrials.gov, last updated 26 Feb 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top